You are here:

Atomoxetine (Strattera®)


Following a full re-submission Atomoxetine (Strattera) is accepted for restricted use within NHS Scotland for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older or in adolescents. It is restricted to use in patients who do not respond to stimulants or in whom stimulants are contraindicated or not tolerated. It is restricted to use by physicians with appropriate knowledge and expertise in treating ADHD. This advice concerns use in children and adolescents only and does not cover use in adults. Atomoxetine (Strattera) it is not a Controlled Drug under the Misuse of Drugs regulations 2001.

Drug Details

Drug Name: Atomoxetine (Strattera®)
SMC Drug ID: 153/05
Manufacturer: Eli Lilly and Company Ltd
Indication: Attention-Deficit/Hyperactivity Disorder
BNF Category:
Sub Category: 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
Submission Type: Resubmission
Status: Superseded
Date Advice Published: 11 July 2005

Archived Advice

Full submission 7 March 2005